Safety and Efficacy of AGN201781 in Neuropathic Pain.
Phase of Trial: Phase II
Latest Information Update: 04 May 2013
At a glance
- Drugs AGN 201781 (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- 23 Oct 2008 Actual patient number (9) added as reported by ClinicalTrials.gov.
- 23 Oct 2008 Actual start date changed from Jan 2008 to Mar 2008 as reported by ClinicalTrials.gov.
- 23 Oct 2008 Planned end date changed from 1 Dec 2009 to 1 Jun 2008 as reported by ClinicalTrials.gov.